JP2010533478A5 - - Google Patents

Download PDF

Info

Publication number
JP2010533478A5
JP2010533478A5 JP2010516305A JP2010516305A JP2010533478A5 JP 2010533478 A5 JP2010533478 A5 JP 2010533478A5 JP 2010516305 A JP2010516305 A JP 2010516305A JP 2010516305 A JP2010516305 A JP 2010516305A JP 2010533478 A5 JP2010533478 A5 JP 2010533478A5
Authority
JP
Japan
Prior art keywords
gamma secretase
seq
ledaefrhds
lvml
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010516305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010533478A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/070012 external-priority patent/WO2009012237A1/en
Publication of JP2010533478A publication Critical patent/JP2010533478A/ja
Publication of JP2010533478A5 publication Critical patent/JP2010533478A5/ja
Withdrawn legal-status Critical Current

Links

JP2010516305A 2007-07-13 2008-07-14 ガンマセクレターゼの阻害剤の基質特異性を同定するための組成物および方法 Withdrawn JP2010533478A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94973807P 2007-07-13 2007-07-13
PCT/US2008/070012 WO2009012237A1 (en) 2007-07-13 2008-07-14 Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase
US12/172,978 US20090023158A1 (en) 2007-07-13 2008-07-14 Compositions and Methods for Identifying Substrate Specificity of Inhibitors of Gamma Secretase

Publications (2)

Publication Number Publication Date
JP2010533478A JP2010533478A (ja) 2010-10-28
JP2010533478A5 true JP2010533478A5 (enExample) 2011-09-01

Family

ID=39739883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010516305A Withdrawn JP2010533478A (ja) 2007-07-13 2008-07-14 ガンマセクレターゼの阻害剤の基質特異性を同定するための組成物および方法

Country Status (5)

Country Link
US (2) US20090023158A1 (enExample)
EP (1) EP2183598A1 (enExample)
JP (1) JP2010533478A (enExample)
CA (1) CA2692604A1 (enExample)
WO (1) WO2009012237A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166110B1 (en) * 2007-06-08 2012-02-22 Eisai R&D Management Co., Ltd. Screening method utilizing novel substrate epha4 for gamma-secretase
EP2177623A4 (en) * 2007-07-19 2010-12-29 Eisai R&D Man Co Ltd SCREENING METHOD USING C-MET, A NEW SUBSTRATE FOR GAMMA SECRETASE
WO2009017234A1 (ja) * 2007-08-01 2009-02-05 Eisai R & D Management Co., Ltd. γ-セクレターゼの新規基質c-Retを利用したスクリーニング方法
US20090163594A1 (en) * 2007-10-31 2009-06-25 Elan Pharmaceuticals, Inc. Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
US8530181B2 (en) * 2007-11-15 2013-09-10 Eisai R&D Management Co., Ltd. Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase
US7892769B2 (en) * 2007-11-30 2011-02-22 Eisai R&D Management Co., Ltd. Processing of EphA4 polypeptide by γ-secretase activity
WO2012081502A1 (ja) 2010-12-17 2012-06-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法
WO2012147798A1 (ja) 2011-04-25 2012-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 EphA4細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
CN110079580B (zh) 2012-06-22 2022-12-06 真蒂奥姆责任有限公司 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法
EP3026122A1 (en) * 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
EP3759127A4 (en) * 2018-03-02 2022-03-30 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
MA56466A (fr) 2019-07-01 2022-05-11 Eisai R&D Man Co Ltd Anticorps anti-epha4
US11913964B2 (en) 2020-02-27 2024-02-27 Adeptrix Corp. Multiplexed bead-based analytical assays
US20230174612A1 (en) * 2020-04-09 2023-06-08 The Regents Of The University Of California Notch receptors with zinc finger-containing transcriptional effector
UY39344A (es) 2020-07-28 2022-02-25 Ionis Pharmaceuticals Inc Compuestos y métodos para reducir la expresión de app

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5605811A (en) 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
DE69426571T2 (de) 1993-10-27 2001-08-09 Elan Pharm Inc TRANSGENE TIERE, DIE APP Allele mit der schwedischen Mutation beherbergen
DE10131899A1 (de) * 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In vitro-Screening-Assay für gamma-Secretase
WO2007058987A1 (en) * 2005-11-10 2007-05-24 Bristol-Myers Squibb Company Methods of identifying compounds that inhibit notch cleavage
US20090163594A1 (en) * 2007-10-31 2009-06-25 Elan Pharmaceuticals, Inc. Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors

Similar Documents

Publication Publication Date Title
JP2010533478A5 (enExample)
JP2013503110A5 (enExample)
JP2008237210A5 (enExample)
WO2010123290A3 (ko) 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법
WO2017070256A3 (en) Method for screening inhibitors of ras
WO2012082056A8 (en) Novel biomarker and uses thereof in diagnosis, treatment of autism
WO2009129311A3 (en) Somatostatin receptor 2 antagonists
ATE410178T1 (de) Oligopeptide zur verringerung erhöhter blutharnstoffkonzentration
WO2007148224A3 (en) Polypeptide
NZ597692A (en) Anti-IGF antibodies
JP2008536483A5 (enExample)
JP2013505287A5 (enExample)
JP2021505620A5 (enExample)
WO2009079212A3 (en) Linked peptide fluorogenic biosensors
WO2005119251A3 (en) Novel means and methods for the treatment of hearing loss and phantom hearing
JP2009527503A5 (enExample)
WO2018175581A8 (en) A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 AND MOUSE Trem2 p.R47H AND METHODS OF USE THEREOF
WO2009107971A3 (ko) 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의 용도
JP2005512547A5 (enExample)
ATE488252T1 (de) Erhöhte transduktion mit abc- transportersubstratenhemmern
JP2006158399A5 (ja) 細胞増殖抑制タンパク質並びにそれを用いる細胞増殖抑制剤、癌診断薬及び癌治療剤
JP2014534173A5 (enExample)
WO2008126783A1 (ja) ジペプチドの製造法
Heidmeier et al. A single amino acid substitution in the measles virus F2 protein reciprocally modulates membrane fusion activity in pathogenic and oncolytic strains
WO2009105780A3 (en) Mntf peptide compositions and methods of use